Full Press Release Details
MARLBOROUGH, Mass. , Sept. 10, 2014 /PRNewswire/ -- Beginning Saturday, Boston Scientific Corporation (NYSE: BSX ) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The company will share results from more than a dozen clinical studies at the 26th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation, being held this year in Washington, D.C. from September 13-17 .
Coronary artery disease, the most common type of heart disease, is prevalent and expensive - each year approximately 380,000 Americans die from coronary artery disease costing the U.S. approximately $108 billion for services, medications and lost productivity[i]. As a result, there is a continuing need for new therapies and technologies to meet this growing global problem.
"Boston Scientific is dedicated to exploring how our technologies can lead to value-driven solutions for patients with cardiovascular disease," said Keith Dawkins , M.D., global chief medical officer, Boston Scientific. "The data we will share further support the body of evidence demonstrating the clinical value of Boston Scientific solutions that assist interventional cardiologists to meet the changing needs of their patients."
Schedule of Key Data Presentations
Boston Scientific data will be presented during oral sessions and as posters. All programs are Eastern Daylight Time and will be held at the Walter E. Washington Convention Center.
Poster Presentations: Saturday, September 13 : 5:00 p.m. – 7:00 p.m. , Lower Level, Hall A
Coronary Artery Stents
Resistant Hypertension
Drug-coated Balloons (DCB)
Oral Presentations: Monday and Tuesday, September 15-16
Left Atrial Appendage Closure (LAAC) Devices
Coronary Artery Stents
Featured Speaker: Monday, September 15 at 3:00 p.m.
The Future of Renal Denervation
In addition to attending the data presentations and featured speaker sessions, conference attendees are invited to visit the Boston Scientific booth (#1400) in the Exhibit Hall, which will be open from 9 a.m. to 5 p.m. Sunday and Monday, September 14 and 15 and from 9 a.m. to 2 p.m. on Tuesday, September 16 .
In the U.S., the SYNERGY™ Stent System and the WATCHMAN™ Left Atrial Appendage (LAA) Closure Device are investigational devices, limited by federal (U.S.) law to investigational use only, and not available for sale. In the U.S., the Lotus™ Valve System and the Vessix Reduce™ Renal Denervation System are under development and not available for use or sale. All aforementioned devices are CE marked in the European Union.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding markets for our products, our business plans, presentations, clinical trials and impact of data, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACTS: Media: Ryan Davenport Global Media Relations Boston Scientific Corporation 612-240-0492 (cell) [email protected]
Investors: Susie Lisa , CFA Investor Relations Boston Scientific Corporation 508-683-5565 (office) [email protected]
[i] http://www.cdc.gov/heartdisease/facts.htm accessed August 26, 2014
SOURCE Boston Scientific Corporation